Managing HIV-hepatitis C co-infection in the era of direct acting antiviralsReportar como inadecuado

Managing HIV-hepatitis C co-infection in the era of direct acting antivirals - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Medicine

, 11:234

HIV thirty years on


Morbidity and mortality from co-morbid hepatitis C HCV infection in HIV co-infected patients are increasing; hence, the management of hepatitis co-infection in HIV is now one of the most important clinical challenges. Therefore, the development of direct acting antivirals DAAs for treatment of HCV has been eagerly awaited to hopefully improve HCV treatment outcome in co-infected individuals. Indeed, the availability of the first HCV protease inhibitors PI boceprevir and telaprevir for HCV genotype 1 patients has changed the gold standard of treating hepatitis C allowing for substantially improved HCV cure rates under triple HCV-PI-pegylated interferon-ribavirin therapy. Moreover, numerous other new DAAs are currently being studied in co-infected patient populations, also exploring shorter treatment durations and interferon-free treatment approaches promising much easier and better tolerated treatment regimens in the near future. Nevertheless, numerous challenges remain, including choice of patients to treat, potential for drug-drug interactions and overlapping toxicities between HIV and HCV therapy. The dramatically improved rates of HCV cure under new triple therapy, however, warrant evaluation of these new treatment options for all co-infected patients.

KeywordsHIV Hepatitis C Direct acting antivirals Interferon Ribavirin Electronic supplementary materialThe online version of this article doi:10.1186-1741-7015-11-234 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Jürgen K Rockstroh - Sanjay Bhagani


Documentos relacionados